If you are not happy with the results below please do another search
Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy does not appear to increase the risk of complications during delivery or negatively impact the health of newborns, according to a new JAMA study.
Bristol Myers Squibb announced that CheckMate -274, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) after surgery in patients with high-risk, muscle-invasive urothelial carcinoma, met primary endpoints of improving disease-free survival (DFS) versus placebo in both all randomized patients and in patients whose tumor cells express PD-L1 ≥1% (programmed death-ligand 1).
President Donald Trump signaled the White House may attempt to override a more stringent guidance for Emergency Use Authorization of a vaccine for the novel coronavirus under consideration by the U.S.Food and Drug Administration (FDA).
A federal appeals court overturned a judge’s approval of a novel plan by lawyers representing cities and counties suing drug companies over the U.S. opioid crisis that would bring every community nationally into their settlement talks.
With $29 million in the company’s pocket, biotech Libra Therapeutics launched to take on neurodegenerative disease, with three pre-clinical programs ready to roll.
Becton Dickinson and Co. reached a $60 million settlement with the attorneys general of 48 U.S. states and Washington D.C., resolving allegations the company concealed the risks of now-discontinued pelvic mesh devices.
After attending several virtual scientific conferences since the start of the COVID-19 lockdown, TBWA\WorldHealth explores which practices should stay, which ones will need to come back, and how pharmaceutical brands can stand out in this medium.
W2O, a leading independent provider of analytics-driven technology-enabled marketing and communications solutions to the healthcare sector, announced the acquisition of Elysia Group, a health economic and outcomes research (HEOR) consulting firm operating in the United States and Asia Pacific.
The U.S. Food and Drug Administration is expected to issue a new and more stringent guidance regarding a potential Emergency Use Authorization (EUA) for a Covid–19 vaccine.
A physician who heads the influential U.S. Food and Drug Administration vaccine advisory committee recused herself from the panel’s review of Covid-19 vaccines because of her role overseeing a clinical trial for Moderna Inc.’s candidate, her spokeswoman told Reuters.